PTN Split History

Palatin Technologies (PTN) has 1 split in our PTN split history database. The split for PTN took place on September 27, 2010. This was a 1 for 10 reverse split, meaning for each 10 shares of PTN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Palatin Technologies conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PTN split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Palatin Technologies shares, starting with a $10,000 purchase of PTN, presented on a split-history-adjusted basis factoring in the complete PTN split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	05/30/2012
End date:	05/27/2022
Start price/share:	$0.61
End price/share:	$0.36
Dividends collected/share:	$0.00
Total return:	-40.98%
Average Annual Total Return:	-5.14%
Starting investment:	$10,000.00
Ending investment:	$5,900.57
Years:	10.00

About Palatin Technologies

Palatin Technologies is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Co.'s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Co.'s primary product, Vyleesi®, is a melanocortin receptor agonist, is an as needed therapy used in anticipation of sexual activity and self-administered in the thigh or abdomen via a single-use subcutaneous auto-injector by premenopausal women with hypoactive sexual desire disorder. According to our PTN split history records, Palatin Technologies has had 1 split.